Literature DB >> 696417

Effect of nifedipine (Adalat) on coronary haemodynamics in patients with coronary arteriosclerotic disease.

S Simonsen, S Nitter-Hauge.   

Abstract

Effects of the new Ca++ antagonist nifedipine (Adalat) on coronary haemodynamics were studied in 8 patients with documented ischaemic heart disease. The continuous infusion thermodilution technique was used to measure cardiac venous blood flow. Sublingual application of 10 mg nifedipine caused a significant increase (16%) in myocardial blood flow and a decrease (18%) in coronary arteriolar resistance at rest, but not during a submaximal atrial pacing test. There was no change in coronary arteriovenous oxygen difference, myocardial oxygen consumption, oxygen consumption per unit of heart rate blood pressure index or left ventricular efficiency index. The effects on the coronary haemodynamics are discussed in relation to the simultaneous changes in general haemodynamics. Systolic aortic pressure was slightly reduced, significantly only at rest, while peripheral vascular resistance decreased and cardiac output increased also during atrial pacing. No change in free fatty acid metabolism was observed. It is concluded that nifedipine is a mild coronary vasodilator. No effect was observed on myocardial oxygen demand. The oxygen cost of left ventricular work was unchanged by the drug both at rest and during the submaximal stress test.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 696417     DOI: 10.1111/j.0954-6820.1978.tb08421.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  11 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Authors:  A Iliopoulou; P Turner; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

Review 3.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

4.  Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Authors:  B Silke; S P Verma; A V Zezulka; S Sharma; G Reynolds; N C Jackson; S Guy; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

5.  Alterations in angina threshold with nifedipine during pacing induced angina.

Authors:  P H Kramer; K Chatterjee; A Schwartz; K Swedberg; J L Rouleau; D Curran; L Blevins; W W Parmley
Journal:  Br Heart J       Date:  1984-09

Review 6.  Role of calcium channel blockers in experimental exercise-induced ischemia.

Authors:  E Thaulow; B D Guth; J Ross
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

7.  Effect of nifedipine on the myocardial and vascular response to myocardial ischemia.

Authors:  D C Homans; E Sublett; X Z Dai; R J Bache
Journal:  Basic Res Cardiol       Date:  1986 Jul-Aug       Impact factor: 17.165

Review 8.  Beta-blockers and calcium antagonists in angina pectoris. The potential role of combination therapy.

Authors:  H J Dargie
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  The acute haemodynamic effects of oral nicardipine.

Authors:  R M McCredie; W B McKenzie; D A McGill
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 10.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.